First Therapy for Advanced Head & Neck Cancer in 10 Years: Johnson & Johnson Secures Accelerated FDA Nod
Johnson & Johnson wins FDA accelerated approval for RYBREVANT FASPRO to treat recurrent or metastatic head and neck cancer.
Stocks · News reference
Chip stocks sold off after a 5% KOSPI plunge, with Micron and Applied Materials sinking, while J&J fell despite a guidance raise.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Johnson & Johnson wins FDA accelerated approval for RYBREVANT FASPRO to treat recurrent or metastatic head and neck cancer.
Capitulation Criteria Please click here for an enlarged chart of Direxion Daily Semiconductor Bull 3X ETF (NYSE:SOXL). Note the following: Semiconductors reflect the AI trade, and SOXL is the momo crowd’s
Gold ETFs face mixed signals as higher interest rates weigh on prices, but potential Iran war resolution, sustained central bank buying, and AI bubble concerns could support the precious metal. Central banks are expected to purchase 50 tons of gold monthly in 2026, while gold's share of global reserves has surpassed U.S. Treasuries, providing long-term tailwinds for gold investments.
U.S. stocks rose, Nasdaq gained ~400 points. Moderna jumped 9.1% on strong Q3 results and higher FY26 guidance; other stocks rallied on results and deals.
Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
The Nasdaq 100 had its worst day since 2020, but credit barely moved. S&P Global's Gavan Nolan tells Benzinga why three stocks stand out.